Decongestion in chronic heart failure
JRSM Cardiovascular Disease · 2026-05 · 15
DOI: 10.1177/20480040261431376 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JRSM Cardiovascular Disease, online erschienen am 25.05.2026. Verfasst von Antohi Laura und 1 weiteren Autor:innen. Beteiligte Einrichtung: Intensive Cardiac Care Unit of the Institute for Cardiovascular Diseases "C.C.Iliescu", Bucharest, Romania. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Congestion drives symptoms and adverse outcomes in heart failure (HF), and loop diuretics remain the cornerstone of decongestion. Yet randomized trials of diuretic strategies and other acute decongestive approaches have not shown mortality benefit, while mechanistic studies demonstrate rapid neurohormonal activation after acute loop diuretic administration. In chronic HF, observational data consistently associate higher loop diuretic requirements—particularly above ∼40 mg/day furosemide equivalent or with dose escalation—with worse prognosis across HF phenotypes, though confounding by disease severity is likely. Decongestion needs vary across the HF trajectory: early guideline-directed therapy provides intrinsic decongestive effects, whereas advanced HF is marked by diuretic resistance and renal vulnerability. Preload-dependent states (notably cardiac amyloidosis and selected HFpEF phenotypes) require especially careful titration to avoid hypovolemia and low output, and robust protocol-level trial evidence is lacking. Contemporary randomized data do not demonstrate superiority of torsemide over furosemide. Small trials and systematic reviews suggest that in carefully selected, stable, non-congested patients, diuretic withdrawal or reduction can be feasible, with ∼25–35% requiring re-initiation within 1–3 months and consistent lowering of renin activity; however, clinical outcome benefit remains unproven. Overall, evidence supports maintaining euvolemia with the lowest effective diuretic dose and considering monitored deprescribing in appropriate low-risk patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Intensive Cardiac Care Unit of the Institute for Cardiovascular Diseases "C.C.Iliescu", Bucharest, Romania.
- University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania.
- Institute Mutualiste Montsouris, Paris, France.
ORCID-Profile: Antohi Laura
Zitieren
APA
Laura, A., & Serban, M. (2026). Decongestion in chronic heart failure. JRSM Cardiovascular Disease, 15. https://doi.org/10.1177/20480040261431376
Vancouver
Laura A, Serban M. Decongestion in chronic heart failure. JRSM Cardiovascular Disease. 2026;15. doi:10.1177/20480040261431376
BibTeX
@article{Laura2026,
author = {Laura, Antohi and Serban, Mihaileanu},
title = {Decongestion in chronic heart failure},
journal = {JRSM Cardiovascular Disease},
year = {2026},
volume = {15},
doi = {10.1177/20480040261431376}
}
EUVIMED